Literature DB >> 3606581

The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

T W Barrowcliffe, S J Havercroft, G Kemball-Cook, U Lindahl.   

Abstract

The influence of Ca2+, phospholipid and Factor V was determined on the rate of inactivation of Factor Xa by antithrombin III, in the absence and in the presence of unfractionated heparin and of three high-affinity heparin oligosaccharides in the Mr range 1500-6000. In the absence of heparin the addition of Ca2+, phospholipid and Factor V caused a 4-fold decrease in rate of inactivation of Factor Xa. As concentrations of unfractionated heparin were increased the protective effect of Ca2+/phospholipid/Factor V was gradually abolished, and at a concentration of 2.4 nM there were no differences in rates of neutralization of Factor Xa in the presence or absence of Ca2+, phospholipid and Factor V. In contrast, heparin decasaccharide (Mr 3000) and pentasaccharide (Mr 1500) fragments were unable to overcome the protective effect of Ca2+/phospholipid/Factor V; in the presence of these components their catalytic efficiencies were 16-fold and 40-fold less respectively than that of unfractionated heparin. A heparin 20-22-saccharide fragment (Mr approx. 6000) gave similar inactivation rates in the presence and in the absence of Ca2+/phospholipid/Factor V. Human and bovine Factor Xa gave similar results. These results indicate that in the presence of Ca2+/phospholipid/Factor V optimum inhibition of Factor Xa requires a saccharide sequence of heparin additional to that involved in binding to antithrombin III. The use of free enzyme for the assessment of anti-(Factor Xa) activity of low-Mr heparin fractions could give misleading results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606581      PMCID: PMC1147810          DOI: 10.1042/bj2430031

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G E Sims
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

2.  The role of platelets in intrinsic factor-Xa formation.

Authors:  P N Walsh; R Biggs
Journal:  Br J Haematol       Date:  1972-06       Impact factor: 6.998

3.  Anticoagulant activities of four unfractionated and fractionated heparins.

Authors:  D A Lane; I R Macgregor; R Michalski; V V Kakkar
Journal:  Thromb Res       Date:  1978-02       Impact factor: 3.944

4.  Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor.

Authors:  E T Yin
Journal:  Thromb Diath Haemorrh       Date:  1975-02-28

5.  Characterization of human, bovine, and horse antithrombin III.

Authors:  K Kurachi; G Schmer; M A Hermodson; D C Teller; E W Davie
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

6.  The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates.

Authors:  G J Modi; M A Blajchman; F A Ofosu
Journal:  Thromb Res       Date:  1984-12-15       Impact factor: 3.944

7.  Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex.

Authors:  E Marciniak
Journal:  Br J Haematol       Date:  1973-03       Impact factor: 6.998

8.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

9.  The acceleration of the inhibition of platelet prothrombinase complex by heparin.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

10.  A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin.

Authors:  M W Pomerantz; W G Owen
Journal:  Biochim Biophys Acta       Date:  1978-07-21
View more
  3 in total

1.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

Review 2.  Novel inhibitors of factor X for use in cardiovascular diseases.

Authors:  F A Spencer; R C Becker
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

3.  Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.

Authors:  F A Spencer; S P Ball; Q Zhang; L Liu; S Benoit; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.